 |
|
|
| The Incomparable Speed of genome-based antibody therapeutics |
The Incomparable Speed of genome-based antibody therapeutics
In this era of hyper-intense global competition, it is said to take at least 20 billion yen and ten years for the development of a new drug. Some estimates are considerably higher. LSBM is pursuing the development of genome-based antibody therapeutics to reduce this cost in time and money by one third, making full use of the technology advantage provided by the unification of systems biology and medicine.
We express functional chemoreceptor proteins which serve as a target for novel drugs, make functional monoclonal antibodies, and develop them for clinical use.
Conventionaly, drug are selected individually through a series of multiple, refining steps. Using budded baculovirus technology, we can express functional proteins encoded by genes from the total genome sequence and select the functional monochlonal antibodies which interact with them. Antibodies are contructed from human genes and then modified by the technology for humanizing antibodies so as to make them less immunoreactive and hence prone to side-effects.
This method is able to reduce eight steps of conventional drug discovery into just three. We can also reduce the risks associated with going forward with a single candidate early in drug development by making many slightly different antibodies against the same target so the one of greatest utility can be selected for further testing at the right time. |
|
The world standard for systematic analysis of a chemoreceptor
In drug development, the most important targets are (1) the receptors on the cell membrane, the so-called G-protein coupled receptors (GPCR), and (2) the nuclear hormone receptors. LSBM is a world leader in the systematic analysis of these two classes of receptors. First of all, we have achieved the technological feats of expressing the GPCR on the surface of an insect virus, and then in reconstituting the functional complex.
LSBM also has access to the intellectual property of The University of Montreal, and formed a global alliance for the exchange of intellectual property with a number of institutions. We are working together with scientists at the Pasteur Institute in France, and the Howard Hughes Medical Research Institute at the University of Texas. To date,
LSBM has expressed most of the known 48 nuclear receptor proteins, on which we have filed intellecutal property claims, and are in the process of establishing 48 monoclonal antibody drug candidates which bind these targets.
LSBM has established a world-class technical method for the analysis of orphan chemoreceptors. |
|
|
